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Objectives: Various minimal clinically important difference (MCID) threshold estimation techniques have been applied to seasonal allergic rhinitis (SAR). The objectives of this study
are to (i) assess the difference in magnitude of alternative SAR MCID threshold estimates and (ii) evaluate the impact of alternative MCID estimates on health technology
assessment (HTA).
Methods: Data describing change from baseline of the reflective Total Nasal Symptom Score (rTNSS) for four intranasal SAR treatments were obtained from United States Food and
Drug Administration-approved prescribing information. Treatment effects were then compared with anchor-based MCID thresholds derived by Barnes et al. and thresholds obtained
from an Agency for Healthcare Research and Quality (AHRQ) panel.
Results: The change in rTNSS score from baseline, represented as the average of the twice-daily recorded scores of the rTNSS, was -2.1 (p< .001) for azelastine hydrochloride
0.10%, 1.35 (p = .014) for ciclesonide, and -1.47 (p< .001) for fluticasone furoate. The change in the rTNSS score from baseline, represented by sum of the AM and PM
score, was -2.7 for MP-AzeFlu (p< .001). The rTNSS change from baseline for each product was compared with anchor-based MCID threshold and the AHRQ panel estimates.
Comparison of the observed treatment effect to the anchor-based and AHRQ panel MCID thresholds results in different conclusions, with clinically important differences being
inferred when anchor-based estimates serve as the reference point.
Conclusion: The AHRQ panel MCID threshold for the rTNSS was twelve times larger than the anchor-based estimates resulting in conflicting recommendations on whether different
SAR treatments provide clinically meaningful benefit.
Keywords: Treatment outcome, Outcome assessment, Seasonal allergic rhinitis, Intranasal corticosteroid, Intranasal combination
In 1993, Kozma and colleagues advanced a new framework for
outcomes research known as the “ECHO” model (1). Using this
new framework, the authors cautioned the medical community
against relying predominantly on efficacy data generated from
clinical trial programs. Rather, the authors suggested that med-
ical decision making should simultaneously consider the eco-
nomic, clinical, and humanistic impacts of alternative treatment
options.
During the same time period, significant advancements
were being made in humanistic outcomes research. Due to
the contributions of interdisciplinary teams around the world,
a proliferation of studies designed to develop and validate
patient reported outcome (PRO) measures occurred. These
scientifically validated measures provided the conduit for gath-
ering general or disease related patient reports on various as-
pects of either their disease or treatment. With the availabil-
ity of patient reported outcomes data, thresholds quantifying a
clinically meaningful improvement could be developed. These
thresholds are now known as minimal clinically important dif-
ference (MCID) thresholds.
Alternative Methods to Derive MCID Thresholds
In recent years, the analytic rigor required to support MCID
threshold estimation has increased. The work of numerous
interdisciplinary teams including biostatisticians, epidemiolo-
gists, physicians, and others have culminated in the identifi-
cation of three different and unique strategies for MCID de-
velopment (2–13). Table 1 provides a summary of the various
techniques to derive MCID threshold estimates and provides
examples of them.
Two quantitative strategies, the distribution-based and
anchor-based MCID threshold estimation methods, have
been advanced more recently in the scientific literature.
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Table 1. General Considerations Related to MCID Threshold Estimate Derivation across Multiple Therapeutic Areas
Threshold estimation MCID threshold estimate derived
technique through this technique Advantages Disadvantages
Technical expert panel estimates (13) 3.6 units Uses expert opinion to guide determination of
MCID
Variation in estimate can occur based on the
expert panel defining the MCID
Distribution-based MCID estimates (14) 0.59 units Assesses the measurement precision of a given
PRO measure
Sample-dependent and difficult to ascertain the
clinical relevance for a given change
Anchor-based MCID estimates (14) 0.23–0.28 units Uses validated PRO data as the anchor for the
estimate and is not sample-dependent
Computationally more involved
MCID, minimum clinically important difference; PRO, patient reported outcome.
Distribution-based MCID estimates report the change in a PRO
measure based on the normal variability observed in the data
and, in general, assume that a change greater than X times the
baseline standard deviation is clinically meaningful (14). The
utility of distribution-based methods may be limited because
they are based on statistical reasoning only. Also, variations
in standard deviations may be observed when PRO data are
obtained from heterogeneous patient populations. Because of
these limitations, anchor-based threshold estimates are gener-
ally perceived as the more rigorous of the two techniques (14).
The third strategy involves the development of MCID threshold
estimates by technical expert panelists. Generally this method
uses clinical experience to derive the estimates instead of pa-
tient reported outcome data. When all three types of thresh-
old estimates are available, thresholds developed based upon
clinical expert opinions have been recommended as a supple-
mentary strategy to existing anchor- and distribution-based es-
timates of MCID (14).
MCID Estimates and Technology Assessment of SAR Treatment
Options: A Case Study
The Total Nasal Symptom Score (TNSS) is a PRO measure re-
quired by marketing authorization authorities (eg, the United
States Food and Drug Administration) to assess patient percep-
tions of the benefits of alternative treatments for seasonal al-
lergic rhinitis (SAR) (15). The reflective Total Nasal Symptom
Score (rTNSS) measures the overall effectiveness of a treat-
ment in controlling symptoms of a pre-specified (e.g., 12 hr)
period of time, and AM and PM reports are typically provided
by patients. Patients report their symptom severity on a scale of
zero (no symptoms) to three (severe symptoms) for up to four
different symptom types. The four symptom types assessed by
the rTNSS include rhinorrhea, nasal congestion, nasal itching,
and sneezing.
Computation of treatment effectiveness using the TNSS
as the primary endpoint for clinical trials for SAR treatments
can be derived through various scoring mechanisms. In gen-
eral, however, treatment effectiveness is defined as the change
in TNSS score from baseline. With respect to calculating the
score at any time point in the study, one technique uses an aver-
age of the score recorded by the patient in the morning and the
evening. Another method of scoring involves summing of the
morning and evening patient reported data.
Using patient reported data derived from the TNSS, Barnes
and colleagues derived MCID estimates using several analyti-
cal techniques. A more in-depth discussion of data sources and
statistical methods used by Barnes et al. to generate MCID esti-
mates using data collected from patients with SAR is described
elsewhere (14). However, one of the MCID thresholds derived
used the preferred direct anchor-based approach with estimated
MCIDs ranging from 0.28 units (95% confidence interval [CI]:
-0.18–0.73) and 0.23 units (95% CI: -0.16–0.62). This estimate
is used to determine whether four different intranasal steroids’
efficacy data as found in the approved prescribing information
would likely be of a magnitude that patients would perceive the
improvements to be clinically meaningful.
Table 2 provides a summary of the data that is used to com-
plete the comparison. The focus of the data presented is solely
on current representatives of intranasal steroid and antihis-
tamine treatments. A wider complementary analysis represent-
ing further treatment options for SAR is described elsewhere
(16). When the absolute value of treatment effect is larger than
the absolute value of the estimated MCID thresholds the treat-
ment is assumed to not only provide a statistically significant
improvement in patient’s symptoms but also a clinically mean-
ingful improvement as well. Data provided in Table 2 illustrate
that all treatments advance both a statistically significant and
clinically meaningful improvement in symptom relief for SAR
patients.
In July 2013, the Agency for Healthcare Research and
Quality (AHRQ) released a comparative effectiveness re-
view of SAR treatments (17). Despite the availability of
anchor-based estimates in 2010 (14), the AHRQ reviewers
used consensus-based technical panel MCID threshold esti-
mates (17). Two panel members considered a 4-point change
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Table 2. Alternative MCID Threshold Estimates
Change from baseline Change from baseline Difference in Equal or exceed
Product N of active ingredient of vehicle placebo control mean changeb P-value MCID (14) the MCID threshold?
Azelastine 0.10% 169 -4.2 -2.1 -2.1 <0.001 0.28 Yes
Ciclesonide 200 mcg 148 -5.26 -4.38 -1.35 0.014 0.28 Yes
Fluticasone furoate 27.5 mcg 127 -3.84 -1.83 -2.07 <0.001 0.28 Yes
MP-AzeFlua 207 -5.6 -2.9 -1.35c <0.001 0.28c Yes
aAssessed using a 24-point scale and normalized to a 12-point scale for purposes of comparison.
bClinically important differences occur when the absolute value of the mean change in rTNSS exceeds the anchor-based MCID threshold estimate.
cWhen multiple values of treatment effect/benefit were reported in the approved prescribing information, the most conservative (lowest) estimate was included and all others were
excluded from the evaluation.
meaningful and one advisor considered a 2-point change mean-
ingful for the TNSS. The panel ultimately concluded that 30%
of the maximum score (i.e., a MCID of 3.6) was an appropri-
ate threshold for SAR technology assessment. The estimates of
this panel may have likely been informed by federal documents
guiding the development of drugs for allergic rhinitis and prior
research by Bousquet and colleagues (15;18). A closer look at
prior research reveals that the primary focus was on the assess-
ment of responsiveness.
While responsiveness and MCID threshold estimation may
be related, the two concepts should not be inferred as being in-
terchangeable as one focuses on individual patient effects and
the other compares population means. Irrespective of the un-
derlying rationale for the selection, a 30% (3.6 units) MCID
threshold derived from the AHRQ panel substantially exceeds
the anchor-basedMCID threshold derived through rigorous sta-
tistical testing of patient reported rTNSS data. Application of
the 3.6 threshold in a manner consistent with the previous eval-
uation would suggest that none of the evaluated intranasal prod-
ucts provide clinically meaningful benefits in patient popula-
tions for which they have been approved and routinely used in
clinical practice.
DISCUSSION
Healthcare decision makers are faced with a difficult task on a
daily basis: assessing the quality of evidence for multiple ther-
apies and interpreting the plethora of data to guide reimburse-
ment and coverage determinations that affect patients’ lives,
physically and monetarily. Within the United States (US), pay-
ers may rely upon data provided within Academy of Managed
Care Pharmacy Format for Formulary Submissions (19) and
supplemental systematic reviews and additional reports. Exter-
nal to the United States, HTA organizations such as the Na-
tional Institute for Health and Care Excellence in the United
Kingdom and the Institute for Quality and Efficiency in Health
Care in Germany provide guidance about whether the value of
an individual product may warrant reimbursement (20;21).
Over the past few decades, researchers have sought to ob-
tain high quality patient reported data and quantify MCID
thresholds that can be used to provide clinicians and reimburse-
ment authorities with a secondary reference threshold to eval-
uate the clinical effectiveness of alternative therapies (12). The
MCID, first defined by Jaeschke et al., is “the smallest differ-
ence in score in the domain of interest which patients would
perceive as beneficial and which would mandate, in the absence
of troublesome side effects and excessive cost, a change in the
patient’s management” (3). Thus, MCIDs may be an important
component of medical decision making if populations of pa-
tients are to maintain sufficient access to treatment options most
likely to provide them with meaningful improvement in symp-
toms.
Furthermore, the case study above demonstrated that reim-
bursement decisions may vary based upon the MCID threshold
estimation technique used. To mitigate the risk of denying pa-
tient access to treatment options that may result in clinically
important improvements in their treatment, all available meth-
ods should be considered and presented in health technology
assessment reports. A critical assessment should discuss differ-
ences in obtained results and check whether the applied MCID
is sensitive for detecting relevant effects.
Before clinicians can routinely use MCID to guide deci-
sions specific to treatment plans of individual patients, much
work is needed by the research community in collaboration
with payers and reimbursement authorities. There may be merit
in bringing experts from around the globe together to dis-
cuss many of the issues identified in this study. For example,
this study identified that the TNSS has favorable endorsement
for marketing authorization and regulatory bodies for use in
pivotal clinical trials. Once a PRO gains this favorable en-
dorsement, should there be an immediate focus on develop-
ing MCID threshold estimates in a uniform manner to guide
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subsequent reimbursement/payer decisions? Also, what entity,
if any, should assume responsibility for monitoring ranges of
MCID threshold estimates and commissioning action when
large variations exist? Finally, what group should be identified
as monitoring the medical literature and designated terms asso-
ciated withMCID threshold estimation? Encouraging standard-
ization around such terminology may support ease of access of
such data when it is needed by clinicians or reimbursement au-
thorities.
As with any evaluation, this review and associated case
study have certain limitations. First, the statistical analysis sup-
porting the derivation of MCIDs using alternative methods is
simply reviewed. Additional detail is provided for the review
in the study by Barnes et al. (14). In addition, the therapeu-
tic alternatives in the evaluation are not complete and only a
few intranasal treatment options for SAR are considered. The
authors make no apology for the simplicity. Quality, trans-
parency and simplicity in decision making should always be
a desired goal in medicine. The narrow focus on a select few
current treatment options for SAR was deemed adequate to il-
lustrate the methodological points and was motivated by the
authors’ awareness that additional research was ongoing to
support further therapeutic options for the treatment of SAR
(16).
CONCLUSION
Medical decision making today is greatly enhanced because of
high quality outcomes research. Clinical trials continue around
the global and provide healthcare decision makers insights on
the potential advantages or disadvantages of alternative treat-
ment options for a given disease state. Reliance, however, on
this information solely for the purposes of medical decision
making continues to be an area of public debate.
With the proliferation of high quality humanistic outcomes
research data, medical decision makers may now have at their
disposal high quality evidence to better understand the influ-
ence of alternative technologies on patient reported health sta-
tus. The translation of PRO data into methodologically sound
MCID estimates and the consistent application of rigorously
developed MCID threshold estimates are important steps in at-
taining the appropriate balance between clinical and humanis-
tic outcomes. Individuals and entities conducting health tech-
nology assessment have a professional and ethical responsi-
bility to use MCID estimates derived from rigorous statistical
analysis of population based patient reported outcomes when
available.
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